Ovarian Cancer - Pipeline Review, H2 2015

Date: December 31, 2015
Pages: 1698
Price:
US$ 2,500.00 US$ 2,125.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O542E62C73FEN
Leaflet:

Download PDF Leaflet

Ovarian Cancer - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Ovarian Cancer - Pipeline Review, H2 2015’, provides an overview of the Ovarian Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ovarian Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Ovarian Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Ovarian Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Ovarian Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Ovarian Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Ovarian Cancer Overview
Therapeutics Development
Ovarian Cancer - Therapeutics under Development by Companies
Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes
Ovarian Cancer - Pipeline Products Glance
Ovarian Cancer - Products under Development by Companies
Ovarian Cancer - Products under Investigation by Universities/Institutes
Ovarian Cancer - Companies Involved in Therapeutics Development
Ovarian Cancer - Therapeutics Assessment
Drug Profiles
Ovarian Cancer - Recent Pipeline Updates 1165
Ovarian Cancer - Dormant Projects 1608
Ovarian Cancer - Discontinued Products 1633
Ovarian Cancer - Product Development Milestones 1639
Appendix 1647

LIST OF TABLES

Number of Products under Development for Ovarian Cancer, H2 2015
Number of Products under Development for Ovarian Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Development by Companies, H2 2015 (Contd..7)
Number of Products under Development by Companies, H2 2015 (Contd..8)
Number of Products under Development by Companies, H2 2015 (Contd..9)
Number of Products under Development by Companies, H2 2015 (Contd..10)
Number of Products under Development by Companies, H2 2015 (Contd..11)
Number of Products under Development by Companies, H2 2015 (Contd..12)
Number of Products under Development by Companies, H2 2015 (Contd..13)
Number of Products under Development by Companies, H2 2015 (Contd..14)
Number of Products under Development by Companies, H2 2015 (Contd..15)
Number of Products under Development by Companies, H2 2015 (Contd..16)
Number of Products under Development by Companies, H2 2015 (Contd..17)
Number of Products under Development by Companies, H2 2015 (Contd..18)
Number of Products under Development by Companies, H2 2015 (Contd..19)
Number of Products under Development by Companies, H2 2015 (Contd..20)
Number of Products under Investigation by Universities/Institutes, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Development by Companies, H2 2015 (Contd..10)
Products under Development by Companies, H2 2015 (Contd..11)
Products under Development by Companies, H2 2015 (Contd..12)
Products under Development by Companies, H2 2015 (Contd..13)
Products under Development by Companies, H2 2015 (Contd..14)
Products under Development by Companies, H2 2015 (Contd..15)
Products under Development by Companies, H2 2015 (Contd..16)
Products under Development by Companies, H2 2015 (Contd..17)
Products under Development by Companies, H2 2015 (Contd..18)
Products under Development by Companies, H2 2015 (Contd..19)
Products under Development by Companies, H2 2015 (Contd..20)
Products under Development by Companies, H2 2015 (Contd..21)
Products under Development by Companies, H2 2015 (Contd..22)
Products under Development by Companies, H2 2015 (Contd..23)
Products under Development by Companies, H2 2015 (Contd..24)
Products under Development by Companies, H2 2015 (Contd..25)
Products under Development by Companies, H2 2015 (Contd..26)
Products under Development by Companies, H2 2015 (Contd..27)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
Ovarian Cancer - Pipeline by 3-V Biosciences, Inc., H2 2015
Ovarian Cancer - Pipeline by 4SC AG, H2 2015
Ovarian Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2015
Ovarian Cancer - Pipeline by AB Science SA, H2 2015
Ovarian Cancer - Pipeline by AbbVie Inc., H2 2015
Ovarian Cancer - Pipeline by Abeona Therapeutics, Inc. , H2 2015
Ovarian Cancer - Pipeline by AbGenomics International, Inc., H2 2015
Ovarian Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015
Ovarian Cancer - Pipeline by Adaptimmune Limited, H2 2015
Ovarian Cancer - Pipeline by Aduro BioTech, Inc., H2 2015
Ovarian Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2015
Ovarian Cancer - Pipeline by Advantagene, Inc., H2 2015
Ovarian Cancer - Pipeline by Advaxis, Inc., H2 2015
Ovarian Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2015
Ovarian Cancer - Pipeline by Aeterna Zentaris Inc., H2 2015
Ovarian Cancer - Pipeline by Agilvax, Inc., H2 2015
Ovarian Cancer - Pipeline by Alchemia Limited, H2 2015
Ovarian Cancer - Pipeline by Alethia Biotherapeutics Inc., H2 2015
Ovarian Cancer - Pipeline by Almac Discovery Limited, H2 2015
Ovarian Cancer - Pipeline by Ambrx, Inc., H2 2015
Ovarian Cancer - Pipeline by Amgen Inc., H2 2015
Ovarian Cancer - Pipeline by Anavex Life Sciences Corp., H2 2015
Ovarian Cancer - Pipeline by ANP Technologies, Inc., H2 2015
Ovarian Cancer - Pipeline by Antoxis Limited, H2 2015
Ovarian Cancer - Pipeline by Aphios Corporation, H2 2015
Ovarian Cancer - Pipeline by Aposense Ltd., H2 2015
Ovarian Cancer - Pipeline by Aprea AB, H2 2015
Ovarian Cancer - Pipeline by arGEN-X BV, H2 2015
Ovarian Cancer - Pipeline by Armour Therapeutics Inc., H2 2015
Ovarian Cancer - Pipeline by Arog Pharmaceuticals, Inc., H2 2015
Ovarian Cancer - Pipeline by ArQule, Inc., H2 2015
Ovarian Cancer - Pipeline by Array BioPharma Inc., H2 2015
Ovarian Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H2 2015
Ovarian Cancer - Pipeline by Ascenta Therapeutics, Inc., H2 2015
Ovarian Cancer - Pipeline by Astellas Pharma Inc., H2 2015
Ovarian Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
Ovarian Cancer - Pipeline by AstraZeneca Plc, H2 2015
Ovarian Cancer - Pipeline by Atara Biotherapeutics, Inc., H2 2015
Ovarian Cancer - Pipeline by ATLAB Pharma SAS, H2 2015
Ovarian Cancer - Pipeline by AVAX Technologies, Inc., H2 2015
Ovarian Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015
Ovarian Cancer - Pipeline by Avipep Pty Ltd, H2 2015
Ovarian Cancer - Pipeline by Azaya Therapeutics, Inc., H2 2015
Ovarian Cancer - Pipeline by Basilea Pharmaceutica AG, H2 2015
Ovarian Cancer - Pipeline by Bavarian Nordic A/S, H2 2015
Ovarian Cancer - Pipeline by Bayer AG, H2 2015
Ovarian Cancer - Pipeline by BeiGene(Beijing) Co.,Ltd, H2 2015
Ovarian Cancer - Pipeline by Beth Israel Deaconess Medical Center, Inc., H2 2015
Ovarian Cancer - Pipeline by BioAtla, LLC, H2 2015
Ovarian Cancer - Pipeline by BioCancell Ltd, H2 2015
Ovarian Cancer - Pipeline by BioMoti Limited, H2 2015
Ovarian Cancer - Pipeline by Bionomics Limited, H2 2015
Ovarian Cancer - Pipeline by BioNumerik Pharmaceuticals, Inc., H2 2015
Ovarian Cancer - Pipeline by Bioo Therapeutics, H2 2015
Ovarian Cancer - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2015
Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Ovarian Cancer - Pipeline by Boston Biomedical, Inc., H2 2015
Ovarian Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2015
Ovarian Cancer - Pipeline by Caladrius Biosciences, Inc. , H2 2015
Ovarian Cancer - Pipeline by Calithera Biosciences, Inc., H2 2015
Ovarian Cancer - Pipeline by CASI Pharmaceuticals Inc., H2 2015
Ovarian Cancer - Pipeline by Cavion LLC, H2 2015
Ovarian Cancer - Pipeline by cCAM Biotherapeutics Ltd., H2 2015
Ovarian Cancer - Pipeline by Cellceutix Corporation, H2 2015
Ovarian Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2015
Ovarian Cancer - Pipeline by Cellectar Biosciences, Inc., H2 2015
Ovarian Cancer - Pipeline by Cellular Biomedicine Group, Inc., H2 2015
Ovarian Cancer - Pipeline by Celon Pharma Sp. z o.o., H2 2015
Ovarian Cancer - Pipeline by Celsion Corporation, H2 2015
Ovarian Cancer - Pipeline by Celyad SA, H2 2015
Ovarian Cancer - Pipeline by Ceronco Biosciences, H2 2015
Ovarian Cancer - Pipeline by Cerulean Pharma, Inc., H2 2015
Ovarian Cancer - Pipeline by Chikujee Therapeutics, H2 2015
Ovarian Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2015
Ovarian Cancer - Pipeline by Clevexel Pharma SAS, H2 2015
Ovarian Cancer - Pipeline by Clovis Oncology, Inc., H2 2015
Ovarian Cancer - Pipeline by CohBar, Inc., H2 2015
Ovarian Cancer - Pipeline by Commence Bio, Inc., H2 2015
Ovarian Cancer - Pipeline by Compliment Corporation, H2 2015
Ovarian Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2015
Ovarian Cancer - Pipeline by CritiTech, Inc., H2 2015
Ovarian Cancer - Pipeline by CTI BioPharma Corp., H2 2015
Ovarian Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015
Ovarian Cancer - Pipeline by CytRx Corporation, H2 2015
Ovarian Cancer - Pipeline by CZ BioMed Corp, H2 2015
Ovarian Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Ovarian Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2015
Ovarian Cancer - Pipeline by DEKK-TEC, Inc., H2 2015
Ovarian Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015
Ovarian Cancer - Pipeline by EirGenix Inc., H2 2015
Ovarian Cancer - Pipeline by Eisai Co., Ltd., H2 2015
Ovarian Cancer - Pipeline by Eli Lilly and Company, H2 2015
Ovarian Cancer - Pipeline by Endocyte, Inc., H2 2015
Ovarian Cancer - Pipeline by EntreChem, S.L., H2 2015
Ovarian Cancer - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015
Ovarian Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2015
Ovarian Cancer - Pipeline by Exelixis, Inc., H2 2015
Ovarian Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Ovarian Cancer - Pipeline by Fortress Biotech, Inc., H2 2015
Ovarian Cancer - Pipeline by Fujifilm Corporation, H2 2015
Ovarian Cancer - Pipeline by Galena Biopharma, Inc., H2 2015
Ovarian Cancer - Pipeline by Galileo Research s.r.l., H2 2015
Ovarian Cancer - Pipeline by GamaMabs Pharma S.A., H2 2015
Ovarian Cancer - Pipeline by Ganymed Pharmaceuticals AG, H2 2015
Ovarian Cancer - Pipeline by Genentech, Inc., H2 2015
Ovarian Cancer - Pipeline by Generex Biotechnology Corporation, H2 2015
Ovarian Cancer - Pipeline by Genmab A/S, H2 2015
Ovarian Cancer - Pipeline by Genor BioPharma Co., Ltd., H2 2015
Ovarian Cancer - Pipeline by GlaxoSmithKline Plc, H2 2015
Ovarian Cancer - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2015
Ovarian Cancer - Pipeline by GlycoNex Inc., H2 2015
Ovarian Cancer - Pipeline by Glycotope GmbH, H2 2015
Ovarian Cancer - Pipeline by GP Pharm, S.A., H2 2015
Ovarian Cancer - Pipeline by Gradalis Inc., H2 2015
Ovarian Cancer - Pipeline by Halozyme Therapeutics, Inc., H2 2015
Ovarian Cancer - Pipeline by Heat Biologics, Inc., H2 2015
Ovarian Cancer - Pipeline by HEC Pharm Co., Ltd., H2 2015
Ovarian Cancer - Pipeline by Hemispherx Biopharma, Inc., H2 2015
Ovarian Cancer - Pipeline by Horizon Pharma Plc, H2 2015
Ovarian Cancer - Pipeline by Huabo Biopharm Co., Ltd., H2 2015
Ovarian Cancer - Pipeline by Ignyta, Inc., H2 2015
Ovarian Cancer - Pipeline by Ildong Pharmaceutical Co., Ltd., H2 2015
Ovarian Cancer - Pipeline by IMMD Inc., H2 2015
Ovarian Cancer - Pipeline by Immune Design Corp., H2 2015
Ovarian Cancer - Pipeline by ImmunoFrontier, Inc., H2 2015
Ovarian Cancer - Pipeline by ImmunoGen, Inc., H2 2015
Ovarian Cancer - Pipeline by Immunomedics, Inc., H2 2015
Ovarian Cancer - Pipeline by Immunovaccine, Inc., H2 2015
Ovarian Cancer - Pipeline by Incyte Corporation, H2 2015
Ovarian Cancer - Pipeline by Inflection Biosciences Limited, H2 2015
Ovarian Cancer - Pipeline by Innate Immunotherapeutics Ltd, H2 2015
Ovarian Cancer - Pipeline by Innate Pharma SA, H2 2015
Ovarian Cancer - Pipeline by INSYS Therapeutics, Inc., H2 2015
Ovarian Cancer - Pipeline by Inventiva SAS, H2 2015
Ovarian Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2015
Ovarian Cancer - Pipeline by Johnson & Johnson, H2 2015
Ovarian Cancer - Pipeline by Juno Therapeutics Inc., H2 2015
Ovarian Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
Ovarian Cancer - Pipeline by Komipharm International Co., Ltd., H2 2015
Ovarian Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
Ovarian Cancer - Pipeline by Laboratoire HRA Pharma, H2 2015
Ovarian Cancer - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2015
Ovarian Cancer - Pipeline by LegoChem Biosciences, Inc, H2 2015
Ovarian Cancer - Pipeline by Lipocure Ltd., H2 2015
Ovarian Cancer - Pipeline by Lymphocyte Activation Technologies, S.A., H2 2015
Ovarian Cancer - Pipeline by Mabion SA, H2 2015
Ovarian Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H2 2015
Ovarian Cancer - Pipeline by MacroGenics, Inc., H2 2015
Ovarian Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2015
Ovarian Cancer - Pipeline by Medestea Research & Production S.p.A., H2 2015
Ovarian Cancer - Pipeline by MediaPharma s.r.l., H2 2015
Ovarian Cancer - Pipeline by MedImmune, LLC, H2 2015
Ovarian Cancer - Pipeline by Medivation, Inc., H2 2015
Ovarian Cancer - Pipeline by MEI Pharma, Inc., H2 2015
Ovarian Cancer - Pipeline by Merck & Co., Inc., H2 2015
Ovarian Cancer - Pipeline by Merck KGaA, H2 2015
Ovarian Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2015

LIST OF FIGURES

Number of Products under Development for Ovarian Cancer, H2 2015
Number of Products under Development for Ovarian Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

3-V Biosciences, Inc.
4SC AG
A. Menarini Industrie Farmaceutiche Riunite Srl
AB Science SA
AbbVie Inc.
Abeona Therapeutics, Inc.
AbGenomics International, Inc.
Acetylon Pharmaceuticals, Inc.
Adaptimmune Limited
Aduro BioTech, Inc.
Advanced Accelerator Applications SA
Advantagene, Inc.
Advaxis, Inc.
Advenchen Laboratories, LLC
Aeterna Zentaris Inc.
Agilvax, Inc.
Alchemia Limited
Alethia Biotherapeutics Inc.
Almac Discovery Limited
Ambrx, Inc.
Amgen Inc.
Anavex Life Sciences Corp.
ANP Technologies, Inc.
Antoxis Limited
Aphios Corporation
Aposense Ltd.
Aprea AB
arGEN-X BV
Armour Therapeutics Inc.
Arog Pharmaceuticals, Inc.
ArQule, Inc.
Array BioPharma Inc.
Arrien Pharmaceuticals, LLC
Ascenta Therapeutics, Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
Atara Biotherapeutics, Inc.
ATLAB Pharma SAS
AVAX Technologies, Inc.
AVEO Pharmaceuticals, Inc.
Avipep Pty Ltd
Azaya Therapeutics, Inc.
Basilea Pharmaceutica AG
Bavarian Nordic A/S
Bayer AG
BeiGene(Beijing) Co.,Ltd
Beth Israel Deaconess Medical Center, Inc.
BioAtla, LLC
BioCancell Ltd
BioMoti Limited
Bionomics Limited
BioNumerik Pharmaceuticals, Inc.
Bioo Therapeutics
Biscayne Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Caladrius Biosciences, Inc.
Calithera Biosciences, Inc.
CASI Pharmaceuticals Inc.
Cavion LLC
cCAM Biotherapeutics Ltd.
Cellceutix Corporation
Celldex Therapeutics, Inc.
Cellectar Biosciences, Inc.
Cellular Biomedicine Group, Inc.
Celon Pharma Sp. z o.o.
Celsion Corporation
Celyad SA
Ceronco Biosciences
Cerulean Pharma, Inc.
Chikujee Therapeutics
Chipscreen Biosciences Ltd
Clevexel Pharma SAS
Clovis Oncology, Inc.
CohBar, Inc.
Commence Bio, Inc.
Compliment Corporation
Critical Outcome Technologies Inc.
CritiTech, Inc.
CTI BioPharma Corp.
Cyclacel Pharmaceuticals, Inc.
CytRx Corporation
CZ BioMed Corp
Daiichi Sankyo Company, Limited
Deciphera Pharmaceuticals, LLC
DEKK-TEC, Inc.
Dr. Reddy's Laboratories Limited
EirGenix Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Endocyte, Inc.
EntreChem, S.L.
Epirus Biopharmaceuticals, Inc.
Esperance Pharmaceuticals, Inc.
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Fortress Biotech, Inc.
Fujifilm Corporation
Galena Biopharma, Inc.
Galileo Research s.r.l.
GamaMabs Pharma S.A.
Ganymed Pharmaceuticals AG
Genentech, Inc.
Generex Biotechnology Corporation
Genmab A/S
Genor BioPharma Co., Ltd.
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd.
GlycoNex Inc.
Glycotope GmbH
GP Pharm, S.A.
Gradalis Inc.
Halozyme Therapeutics, Inc.
Heat Biologics, Inc.
HEC Pharm Co., Ltd.
Hemispherx Biopharma, Inc.
Horizon Pharma Plc
Huabo Biopharm Co., Ltd.
Ignyta, Inc.
Ildong Pharmaceutical Co., Ltd.
IMMD Inc.
Immune Design Corp.
ImmunoFrontier, Inc.
ImmunoGen, Inc.
Immunomedics, Inc.
Immunovaccine, Inc.
Incyte Corporation
Inflection Biosciences Limited
Innate Immunotherapeutics Ltd
Innate Pharma SA
INSYS Therapeutics, Inc.
Inventiva SAS
Jiangsu Kanion Pharmaceutical Co., Ltd.
Johnson & Johnson
Juno Therapeutics Inc.
Karyopharm Therapeutics, Inc.
Komipharm International Co., Ltd.
Kyowa Hakko Kirin Co., Ltd.
Laboratoire HRA Pharma
Lee's Pharmaceutical Holdings Limited
LegoChem Biosciences, Inc
Lipocure Ltd.
Lymphocyte Activation Technologies, S.A.
Mabion SA
MabVax Therapeutics Holdings, Inc.
MacroGenics, Inc.
Mebiopharm Co., Ltd.
Medestea Research & Production S.p.A.
MediaPharma s.r.l.
MedImmune, LLC
Medivation, Inc.
MEI Pharma, Inc.
Merck & Co., Inc.
Merck KGaA
Merrimack Pharmaceuticals, Inc.
Merus B.V.
Millennium Pharmaceuticals, Inc.
MolMed S.p.A.
Momenta Pharmaceuticals, Inc.
Monopar Therapeutics LLC
Morphotek, Inc.
Mundipharma International Ltd
Mycenax Biotech Inc.
Natco Pharma Limited
Nektar Therapeutics
Nemucore Medical Innovations, Inc.
Neovacs SA
Nerviano Medical Sciences S.r.l.
Neurimmune Holding AG
Northwest Biotherapeutics, Inc.
Novartis AG
NuCana BioMed Limited
Oasmia Pharmaceutical AB
OBI Pharma, Inc.
Omeros Corporation
Omnitura Therapeutics Inc.
OncBioMune Pharmaceuticals Inc.
Oncobiologics, Inc.
Oncodesign SA
OncoHoldings, Inc.
Oncolix, Inc.
Oncology Research International Limited
Oncolytics Biotech Inc.
OncoMed Pharmaceuticals, Inc.
Oncothyreon Inc.
Ono Pharmaceutical Co., Ltd.
Onyx Pharmaceuticals, Inc.
Optimum Therapeutics, LLC
ORCA Therapeutics B.V.
OSE Pharma SA
Otsuka Holdings Co., Ltd.
Oxford BioMedica Plc
OXiGENE, Inc.
Panacela Labs, Inc.
PDS Biotechnology Corporation
PEP-Therapy SAS
Pfizer Inc.
Pharma Mar, S.A.
Pharmacyclics, Inc.
Pharmicell Co., Ltd.
Polaris Pharmaceuticals, Inc.
Polyplus-Transfection SA
Pono Pharma
Precision Biologics, Inc.
Prima BioMed Ltd.
PsiOxus Therapeutics Limited
Puma Biotechnology, Inc.
Qu Biologics Inc.
Quantum Pharmaceuticals
Quest PharmaTech Inc.
Recepta Biopharma S.A.
Rexahn Pharmaceuticals, Inc.
Rigontec GmbH
Rosetta Genomics, Ltd.
Samyang Holdings Corporation
Sanofi
Sanofi Pasteur SA
Sapvax
SATT Nord
Scancell Holdings Plc
Sellas Inc.
Serina Therapeutics, Inc.
Shenzen SiBiono GeneTech Co., Ltd
Sigma-Tau S.p.A.
Soricimed Biopharma Inc.
Sorrento Therapeutics, Inc.
Sotio a.s.
Spectrum Pharmaceuticals, Inc.
Sphaera Pharma Pvt. Ltd.
Starpharma Holdings Limited
Sumitomo Dainippon Pharma Co., Ltd.
Sun Pharma Advanced Research Company Ltd.
Supratek Pharma Inc.
Susavion Biosciences, Inc.
Synta Pharmaceuticals Corp.
Takeda Pharmaceutical Company Limited
Takis S.r.l.
TapImmune Inc.
Tara Immuno-Oncology Therapeutics LLC
Targovax AS
Tesaro, Inc.
TetraLogic Pharmaceuticals
Theravectys SA
TVAX Biomedical, Inc.
TyrNovo Ltd.
Tyrogenex, Inc.
ValiRx Plc
Vascular Biogenics Ltd.
VentiRx Pharmaceuticals, Inc.
Verastem, Inc.
VG Life Sciences, Inc.
VioQuest Pharmaceuticals, Inc.
ViraTherapeutics GmbH
Viventia Bio Inc.
Welichem Biotech Inc.
Zensun (Shanghai) Sci & Tech Co., Ltd
Skip to top


Ovarian Cancer - Pipeline Review, 2015 US$ 3,200.00 Oct, 2015 · 174 pages
Epithelial Ovarian Cancer - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
Metastatic Ovarian Cancer - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
Polycystic Ovarian Syndrome - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 54 pages

Ask Your Question

Ovarian Cancer - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: